683 Capital Management LLC Makes New Investment in Climb Bio, Inc. $CLYM

683 Capital Management LLC acquired a new position in shares of Climb Bio, Inc. (NASDAQ:CLYM) in the 4th quarter, Holdings Channel.com reports. The firm acquired 201,652 shares of the company’s stock, valued at approximately $807,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Peapod Lane Capital LLC boosted its holdings in Climb Bio by 0.7% during the fourth quarter. Peapod Lane Capital LLC now owns 565,992 shares of the company’s stock worth $2,264,000 after buying an additional 4,126 shares during the last quarter. Blair William & Co. IL bought a new position in shares of Climb Bio during the fourth quarter worth $44,000. ADAR1 Capital Management LLC grew its holdings in shares of Climb Bio by 11.9% in the 3rd quarter. ADAR1 Capital Management LLC now owns 133,530 shares of the company’s stock valued at $268,000 after buying an additional 14,210 shares during the period. AQR Capital Management LLC acquired a new position in shares of Climb Bio in the 1st quarter valued at $27,000. Finally, UBS Group AG grew its holdings in shares of Climb Bio by 6.0% in the 3rd quarter. UBS Group AG now owns 405,404 shares of the company’s stock valued at $815,000 after buying an additional 22,922 shares during the period. 69.76% of the stock is owned by institutional investors.

Climb Bio Stock Performance

NASDAQ:CLYM opened at $11.34 on Thursday. Climb Bio, Inc. has a 52-week low of $1.16 and a 52-week high of $12.48. The company has a market cap of $649.33 million, a P/E ratio of -14.54 and a beta of 0.09. The stock’s 50-day simple moving average is $10.23 and its 200 day simple moving average is $6.93.

Climb Bio (NASDAQ:CLYM) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.06. As a group, equities analysts predict that Climb Bio, Inc. will post -0.87 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Truist Financial assumed coverage on shares of Climb Bio in a report on Tuesday, March 17th. They issued a “buy” rating and a $17.00 price target for the company. HC Wainwright boosted their price target on shares of Climb Bio from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Wedbush reissued an “outperform” rating and issued a $17.00 price target on shares of Climb Bio in a report on Friday, June 12th. Chardan Capital initiated coverage on Climb Bio in a report on Tuesday, May 5th. They set a “buy” rating and a $22.00 price objective on the stock. Finally, B. Riley Financial initiated coverage on Climb Bio in a report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $21.73.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.